# Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

> **NCT07382544** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Cancer
- Solid Tumor

## Interventions

- **DRUG:** MRTX1719
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT07382544
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2030-01-31
- **Final completion:** 2032-01-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382544, "Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07382544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*